10.11.19
6 min. Read

Roche-Genentech to develop in-house digital therapeutic. UHC. Livongo.

Issue 023.

Get E&O weekly. | Subscribe | Digital health research from Brian Dolan.

Welcome to E&O.

Last week's newsletter had a 71 percent open rate. Here's what's happening this week:

  • A warm welcome to all of the new E&O enterprise subscribers! And a reminder: If your company has an enterprise subscription, any and all of your coworkers are entitled to an E&O membership. So feel free to have your colleagues send me an email if they'd like full access. For those of you looking to make E&O available to your entire team or company, head on over to the E&O pricing page here for more info.
  • Better Therapeutics published its fifth study: This one assesses economic impact of the company's digital therapeutics for type 2 diabetes and hypertension. Read this summary or the full study here.
  • Biofourmis announced a second FDA 510(k) clearance (first one was in May), this time for its Biovitals

Paying Subscribers Only

It's a good one, too.
This digital health research is for paying Exits & Outcomes subscribers only. Subscribe now to read this article, get the weekly newsletter, and receive unrestricted access to past and future research from the Exits & Outcomes archives. Smash the link above or below to subscribe yourself -- or head over to our pricing page to subscribe your team or your whole company!
×

Full access to E&O's research and newsletters.

Get the subscribers-only newsletters + research reports + databases
Help me get ahead. $200/year

Prescription Digital Therapeutics

All Newsletters
    215 articles
  • First
  • Previous
    • 1 of 22
  • Next
  • Last
Is it enough? Early MAC pricing for new digital mental health treatment code
4.18.25
6 min. Read
Scoop: Whoop’s first FDA clearance (and what will likely be its second)
4.10.25
7 min. Read
NightWare revenue. Oui terminates trial. 2025 FDA guidance priorities, posteriorities
1.17.25
7 min. Read
NY Medicaid won’t pay for Freespira, CanvasDx. Insolvent Mahana’s first asset sale.
12.13.24
9 min. Read
Final Fee Schedule: How CMS tweaked its digital mental health treatment G-codes
11.01.24
5 min. Read
CMS prices MedRhythms InTandem. Big Health courts health systems
10.11.24
4 min. Read
Mahana Therapeutics’ insolvency. FDA clears Happy Ring (Tinder founder’s smart ring)
10.04.24
6 min. Read
Flashback: How Proteus Digital Health’s outcomes-based pricing worked for Tennessee Medicaid
9.20.24
5 min. Read
Are the Digital Mental Health Treatment G Codes necessary? Or RTM dupes?
7.12.24
7 min. Read
Which PDTs are still around? New bill in Congress.
6.28.24
10 min. Read
  • First
  • Previous
    • 1 of 22
  • Next
  • Last